• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CD80 Gene Record

  • Summary
  • Interactions
  • Claims
  • CD80 941 Druggable Genome

    Alternate Names:

    941
    CD80 MOLECULE
    CD80
    B7
    B7-1
    B7.1
    BB1
    CD28LG
    CD28LG1
    LAB7
    112203
    1700
    ENSG00000121594
    OTTHUMG00000159419
    P33681
    T-LYMPHOCYTE ACTIVATION ANTIGEN CD80
    ACTIVATION B7-1 ANTIGEN
    CTLA-4 COUNTER-RECEPTOR B7.1
    CD80_HUMAN
    CD_antigen=CD80
    T58238

    Gene Info:

    Target Class Receptors
    Target Subclass Receptor
    Target Subclass T-cell surface receptor
    Target Subclass Other
    Transmembrane Helix Count 1
    Target Subclass Ig
    Target Main Class Receptors
    Gene Biotype PROTEIN_CODING
    (4 More Sources)

    Gene Categories: Category Details

    CELL SURFACE
    EXTERNAL SIDE OF PLASMA MEMBRANE
    DRUGGABLE GENOME

    Publications:

    Tedesco Silva et al., 2006, Immunotherapy for De Novo renal transplantation: what's in the pipeline?, Drugs
    Yabu et al., 2007, Novel immunosuppression: small molecules and biologics., Semin. Nephrol.
    Lumsden et al., 2000, Differential requirement for CD80 and CD80/CD86-dependent costimulation in the lung immune response to an influenza virus infection., J. Immunol.
    Nogid et al., 2006, Role of abatacept in the management of rheumatoid arthritis., Clin Ther
    Kremer, 2005, Selective costimulation modulators: a novel approach for the treatment of rheumatoid arthritis., J Clin Rheumatol
    Scheinfeld, 2006, Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists., J Dermatolog Treat
    Vincenti et al., 2007, T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation., Annu. Rev. Med.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Reynolds et al., 2007, Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis., Pharmacotherapy
    Weyand et al., 2006, T-cell-targeted therapies in rheumatoid arthritis., Nat Clin Pract Rheumatol
    Hervey et al., 2006, Abatacept., BioDrugs
    Maxwell et al., 2010, Abatacept for rheumatoid arthritis: a Cochrane systematic review., J. Rheumatol.
    Komi et al., 2000, Toremifene increases the expression of intercellular adhesion molecule-1 (ICAM-1) on MCF-7 breast cancer cells and Jurkat cells., Scand. J. Immunol.
    Kawazu et al., 2000, Suppressive activity of a macrolide antibiotic, roxithromycin on co-stimulatory molecule expression on mouse splenocytes in vivo., Mediators Inflamm.
    Yang et al., 2002, Hyaluronic acid and chondroitin sulphate A rapidly promote differentiation of immature DC with upregulation of costimulatory and antigen-presenting molecules, and enhancement of NF-kappaB and protein kinase activity., Scand. J. Immunol.
    Gottlieb et al., 2004, Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis., Clin. Immunol.
    Leonard et al., 2007, A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma., Ann. Oncol.
    Czuczman et al., 2005, Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma., J. Clin. Oncol.
    Boylan et al., 1999, CD80 (B7-1) and CD86 (B7-2) expression in multiple sclerosis patients: clinical subtype specific variation in peripheral monocytes and B cells and lack of modulation by high dose methylprednisolone., J. Neurol. Sci.
  • GALIXIMAB   CD80

    Interaction Score: 46.37

    Interaction Types & Directionality:
    antibody (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction T-lymphocyte activation antigen CD80 inhibitor
    Direct Interaction yes
    Trial Name galiximab

    PMIDs:
    15093549 17470451 15994148


    Sources:
    TdgClinicalTrial ChemblInteractions TTD

  • ABATACEPT   CD80

    Interaction Score: 38.64

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name CTLA4
    Novel drug target Established target
    Direct Interaction yes

    PMIDs:
    10604996 17212998 16357751 16971318 17020493 11752352 18041889 16932686 16573350 20080922


    Sources:
    TdgClinicalTrial ChemblInteractions NCI TEND TTD

  • BELATACEPT   CD80

    Interaction Score: 10.3

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name belatacept, BMS-224818, LEA29y
    Novel drug target Established target
    Mechanism of Interaction T-lymphocyte activation antigen CD80 inhibitor

    PMIDs:
    16978033 17616278


    Sources:
    TdgClinicalTrial ChemblInteractions

  • VIAGENPUMATUCEL-L   CD80

    Interaction Score: 3.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • TOREMIFENE   CD80

    Interaction Score: 2.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10632979


    Sources:
    NCI

  • ROXITHROMYCIN   CD80

    Interaction Score: 1.93

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10877454


    Sources:
    NCI

  • METHYLPREDNISOLONE   CD80

    Interaction Score: 1.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10521545


    Sources:
    NCI

  • CYCLOSPORINE   CD80

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11841687


    Sources:
    NCI

  • Ensembl: ENSG00000121594

    • Version: 101_38

    Alternate Names:
    CD80 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • TEND: P33681

    • Version: 01-August-2011

    Alternate Names:
    P33681 Uniprot Accession
    CD80 Gene Symbol
    ENSG00000121594 Ensembl Gene Id

    Gene Info:
    Target Subclass Other
    Transmembrane Helix Count 1
    Target Subclass Ig

    Publications:

  • TdgClinicalTrial: P33681

    • Version: January-2014

    Alternate Names:
    CD80 Gene Symbol

    Gene Info:
    Target Class Receptors
    Target Subclass Receptor
    Target Subclass T-cell surface receptor

    Publications:

  • NCI: CD80

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Lumsden et al., 2000, Differential requirement for CD80 and CD80/CD86-dependent costimulation in the lung immune response to an influenza virus infection., J. Immunol.
    Komi et al., 2000, Toremifene increases the expression of intercellular adhesion molecule-1 (ICAM-1) on MCF-7 breast cancer cells and Jurkat cells., Scand. J. Immunol.
    Poloso et al., 2001, Development of therapeutic vaccines by direct modification of cell membranes from surgically removed human tumor tissue with immunostimulatory molecules., Vaccine

  • HingoraniCasas: ENSG00000121594

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000121594 Gene Symbol
    CD80 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • ChemblInteractions: CD28LG

    • Version: chembl_23

    Alternate Names:
    CD28LG1 GENE_SYMBOL
    LAB7 GENE_SYMBOL
    CD80 GENE_SYMBOL

    Gene Info:

    Publications:

  • GO: CD80

    • Version: 01-February-2022

    Alternate Names:
    CD28LG GO Gene Synonym
    CD28LG1 GO Gene Synonym
    LAB7 GO Gene Synonym

    Gene Info:

    Gene Categories:
    CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE

    Publications:

  • TTD: Activation B7-1 antigen

    • Version: 2020.06.01

    Alternate Names:
    CD80 TTD Gene Abbreviation
    T58238 TTD Target ID

    Gene Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21